Researchers have found that the immune system may play a role in preventing premature labour and birth.
It was previously known that cytokines -- small proteins that alert the body to infection and cause inflammation -- are found in the amniotic fluid of many women who gave birth prematurely.
Although the immune system ought to attack the foetus, a foreign body in the mother's womb, something blocks that from happening during pregnancy.
It means that the protection is stopped for some women, causing premature labour, the researchers said.
"There's a lot of anti-inflammatory mechanisms that prevent the foetus from being rejected. So we thought maybe dangerous inflammation, that can break down the tolerance barrier, could mediate the start-up of birth even -- or especially -- premature birth," said Anthony Vella, an immunologist at the University of Connecticut.
In the study, published in the journal Reproductive Sciences, the team took cells from the female reproductive tract and the amniotic fluid that surrounds foetuses in the womb, and exposed them to pieces of bacteria in the lab.
As expected, the cells produced lots of cytokines, but these were not primarily the inflammation causing ones.
Instead, they saw much more granulocyte-macrophage colony-stimulating factor (GM-CSF) than they expected.
GM-CSF is a kind of cytokine that causes cells to grow up quickly and become bacteria-eating macrophages. The population of macrophages in pregnant women does tend to ramp up right before the women gives birth. It is, however, unclear if that is directly connected to birth, or a side effect of another process.
The finding that GM-CSF is released in response to perceived bacterial infection is intriguing because there's already a drug available that blocks GM-CSF.
Treating pregnant mice with this drug sharply reduced pre-term birth in mice that had been exposed to pieces of dangerous bacteria. If preventing premature births could be that straightforward, it would be a game changer, the researchers noted.
"We're hoping to do more immune mechanism studies in mice. And in the not-too-distant future, we hope to start looking at human studies," the researchers noted.
--IANS
rt/mag/bg
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
